Cabio Biotech Wuhan Co., Ltd. (688089)
Market Closed
11 Aug, 06:57
SSE SSE Primary ¥
7. 85
-0.02
-0.2541%
¥
3.95B Market Cap
- P/E Ratio
0.8% Div Yield
2.1M Volume
- Eps
¥ 7.87
Previous Close Want to track 688089 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
688089 closed today lower at ¥7.85, a decrease of -0.2541% from yesterday's close, completing a monthly decrease of -26.6355% or -¥2.85. Over the past 12 months, 688089 stock lost -66.1638%.
688089 pays dividends to its shareholders, with the most recent payment made on Jul 10, 2025. The next estimated payment will be in 1 month ago on Jul 10, 2026 for a total of ¥0.20094.
The last earnings report, released on Apr 24, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Cabio Biotech Wuhan Co., Ltd. has completed 1 stock splits, with the recent split occurring on Jul 18, 2023.
The company's stock is traded on one exchange.
688089 Chart
People also search for
Cabio Biotech Wuhan Co., Ltd. (688089) FAQ
What is the stock price today?
The current price is ¥7.85.
On which exchange is it traded?
Cabio Biotech Wuhan Co., Ltd. is listed on SSE.
What is its stock symbol?
The ticker symbol is 688089.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.8%.
What is its market cap?
As of today, the market cap is 3.95B.
Has Cabio Biotech Wuhan Co., Ltd. ever had a stock split?
Cabio Biotech Wuhan Co., Ltd. had 1 splits and the recent split was on Jul 18, 2023.
Cabio Biotech Wuhan Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Dewei Yi CEO | SSE Exchange | CNE100005X31 ISIN |
| CN Country | 508 Employees | 10 Jul 2025 Last Dividend | 18 Jul 2023 Last Split | - IPO Date |
Overview
Cabio Biotech (Wuhan) Co., Ltd., established in 1999 and operating out of Wuhan, the People's Republic of China, is a prominent enterprise in the biotechnology sector. The company specializes in the development, production, and marketing of critical nutritional components such as arachidonic acid (ARA), docosahexaenoic acid (DHA), and beta-carotene. These ingredients are essential for various applications, including infant formula and health food products. Cabio caters to both domestic and international markets, fulfilling the needs of manufacturers who prioritize the health and nutritional value of their products.
Products and Services
Cabio Biotech offers a diverse portfolio of products aimed at improving health and nutrition in various industries. These include:
- Infant Formula Food: Enriched with ARA and DHA, Cabio's ingredients are critical for the development of infants, playing a vital role in the development of the brain and eyes.
- Health Food & Dietary Supplements: Offering a range of products that are fortified with essential oils and beta-carotene, these supplements aim to enhance overall health and well-being among consumers.
- Special Medical Purposes: Products designed for specific dietary management that can only be consumed or administered under the supervision of a doctor, catering to people with particular medical or dietary needs.
- Pet Nutrition Food: Ingredients that contribute to the health and growth of pets, ensuring they receive the necessary nutritional benefits.
- Economic Animal Feed: Supplements that improve the nutritional value of feed, promoting healthier livestock and poultry.
- Personal Care and Cosmetics: Beta-carotene is utilized in the cosmetic and personal care industry for its antioxidant properties and as a colorant, contributing to skin health and appearance.
Contact Information
Address: No. 999 high-tech Avenue, Wuhan, China, 430073
Phone: 86 27 6784 5351
Website: https://www.cabio.cn
